In this article, we will take a look at the 13 Best March Dividend Stocks to Buy.

An American asset management company, Nuveen, said dividend income can serve as a steady complement to capital appreciation, especially during periods of market uncertainty. Dividends can help smooth overall returns and reduce the impact of market swings. When stock prices move sharply, companies with strong balance sheets and reliable dividend growth often provide a level of stability that supports long-term performance.

The firm noted that although share buybacks have exceeded dividends in recent years, dividends have remained more consistent. Unlike buybacks, which tend to rise and fall depending on market conditions, dividend payments have followed a steadier upward path over time. Nuveen expects dividend growth across the S&P 500 to remain strong in 2026. This outlook is tied to solid earnings growth and improved cash flow. Changes in how companies account for R&D and capital spending could also give them more room to increase dividends.

Dividends are unlikely to overtake share repurchases, but companies may lean more toward dividend increases next year. With valuations still elevated, dividends offer a more predictable way to return capital to shareholders. The firm sees the strongest dividend growth coming from information technology, financials, and industrials. Meanwhile, sectors such as consumer staples, utilities, and consumer discretionary, which already offer higher yields, are expected to deliver more modest dividend growth.

Given this, we will take a look at some of the best dividend stocks in March.

Our Methodology:

For this list, we selected dividend stocks that will trade ex-dividend in March 2026. The ex-dividend date indicates the cutoff day to buy a stock to receive its upcoming dividend payment. The stocks are ranked according to their ex-dividend dates.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

13. eBay Inc. (NASDAQ:EBAY)

Ex-Dividend Date: March 6

On February 26, Bloomberg reported that eBay Inc. (NASDAQ:EBAY) plans to cut about 800 jobs, which account for roughly 6% of its full-time workforce. The company indicated that the decision was part of an effort to better align staffing levels with its strategic priorities. At the same time, eBay said it will continue hiring in areas it considers critical to its future growth. The company made the following statement:

“We are taking steps to reinvest across our business and align our structure with our strategic priorities, which will affect certain roles across our workforce. We are grateful for the contributions of the employees impacted and are committed to supporting them with care and respect.”

The announcement came just one week after eBay revealed plans to acquire secondhand fashion platform Depop for about $1.2 billion, a move aimed at attracting younger shoppers. It also followed a strong quarterly report, where revenue rose 15% year over year to $3 billion in the fourth quarter, beating analyst expectations.

This marks the third round of layoffs in the past three years. In early 2024, eBay eliminated around 1,000 positions, or about 9% of its workforce, explaining that labor expenses had grown faster than the business itself. A year earlier, in early 2023, the company cut roughly 500 jobs, or 4% of its staff, pointing to weaker consumer spending after the surge in online shopping during the pandemic began to ease.

eBay Inc. (NASDAQ:EBAY) operates as a global commerce platform, using its technology to connect buyers and sellers across more than 190 markets worldwide.

12. Viatris Inc. (NASDAQ:VTRS)

Ex-Dividend Date: March 9

On February 27, UBS raised its price recommendation on Viatris Inc. (NASDAQ:VTRS) to $20 from $18. It maintained a Buy rating on the stock. The firm noted that Viatris met its Q4 cost-saving goals and issued FY26 guidance that came in above consensus expectations. Still, the shares dropped 5%, following strong gains earlier in the year. The analyst told investors that the upcoming March 19 investor event could be important. It may lay out a path toward mid-single-digit revenue growth. UBS also said ongoing cost reductions could support a teen-level EPS compound annual growth rate, which may help drive meaningful multiple expansion over time.

The company also reported its Q4 2025 results. CEO Scott Smith said 2025 had been a strong year for Viatris. He stated that the company delivered solid financial performance and had positioned itself to enter a phase of sustainable long-term growth beginning in 2026. Smith reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion, pointing to the overall strength of the business.

He also highlighted progress in the company’s pipeline. Five Phase III studies delivered positive results, which he described as an important milestone. He added that enrollment in key programs, including cenerimod and selatogrel, was moving forward and expected to be completed in 2026. Smith said Viatris returned more than $1 billion to shareholders during the year through dividends and share repurchases. He also pointed to the completion of 60 regional transactions. These included the acquisition of Aculys Pharma in Japan, which he described as part of the company’s broader strategic plan.

Smith said the company expects to generate about $650 million in gross cost savings over three years. He added that up to $250 million of those savings will be reinvested into growth initiatives. He also said the company had prepared for a potential FDA reinspection of its Indore facility. Steps were taken to build operational redundancies, with the goal of maintaining continuity and stability.

Viatris Inc. (NASDAQ:VTRS) operates as a global healthcare company. Its business spans Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment includes its primary operations in North America and Europe.